# Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/TIL/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: TIL
Company: Instil Bio
Source: Instil Bio
Published: 2026-05-15 11:00 EST
Original Source URL: https://ir.instilbio.com
## Summary

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update.

## Article Body
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update.
## Recent Company News
- 2026-05-15 11:00 EST — [Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-03-27 11:00 EST — [Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2026-01-06 12:00 EST — [Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco](https://biopharmsignal.com/news/TIL/instil-bio-s-subsidiary-discontinues-clinical-development-of-axn-2510-and-terminates-license-and-collaboration-agreement-with-immuneonco) — Source: Instil Bio
- 2025-11-13 12:00 EST — [Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TIL/instil-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update) — Source: Instil Bio
- 2025-09-10 11:00 EST — [Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)](https://biopharmsignal.com/news/TIL/instil-bio-announces-immuneonco-s-presentation-of-2510-monotherapy-data-in-patients-with-2l-squamous-nsclc-at-the-2025-world-conference-on-lung-cancer-wclc) — Source: Instil Bio
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)